Manufacturer expands access to prostate drug


Do you have any prostate cancer patients whose treatments have failed? If so, there's a new option they can try. It's satraplatin, which GPC Biotech is offering under an expanded-access program. Called the Satraplatin Expanded Rapid Access (SPERA) protocol, the program offers hormone-refractory prostate cancer patients whose first-line chemotherapy has failed the investigational drug on a gratis basis. Satraplatin is a fourth-generation oral drug in the platinum family of compounds. For more information, contact 1-(800) 349-8086 or

Related Videos
© 2024 MJH Life Sciences

All rights reserved.